scholarly journals Morning Spot Urine Glucose-to-Creatinine Ratios Predict Overnight Urinary Glucose Excretion in Patients With Type 2 Diabetes

2017 ◽  
Vol 37 (1) ◽  
pp. 9-17 ◽  
Author(s):  
So Ra Kim ◽  
Yong-ho Lee ◽  
Sang-Guk Lee ◽  
Sun Hee Lee ◽  
Eun Seok Kang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Urinary Glucose Excretion ◽  
Urine Glucose ◽  
Spot Urine ◽  
Urinary Glucose ◽  
Glucose Excretion

Dapagliflozin: A new class of drug in the treatment of Type 2 diabetes

2016 ◽  
Vol 2 (3) ◽  
pp. 157-159
Author(s):  
N. Surendra Reddy ◽  
P. Lakshmi ◽  
G. Divya ◽  
T. S. Durga Prasad ◽  
D. Ranganayakulu
Keyword(s):  
Type 2 Diabetes ◽  
New Class ◽  
Oral Medications ◽  
Urinary Glucose ◽  
Diet And Exercise ◽  
The Us ◽  
The Common ◽  
Tract Infections ◽  
Glucose Excretion

Sodium-glucose co-transporter (SGLT) inhibitors are a new group of oral medications used for treating type 2 diabetes. Dapagliflozin was approved in January 8th, 2014 and is the second selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2) to be marketed in the US. It is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 Diabetes Mellitus (T2DM).It is available 5mg and 10 mg in film coated tablets. It acts by inhibiting SGLT2 decreases plasma glucose by increasing urinary glucose excretion. The common adverse reactions are genital mycotic infection, nasopharyngitis, urinary tract infections, back pain, urination increase, nausea, influenza. It is contraindicated in hypertension, renal impairment, hypoglycemia, genital myotic infections and bladder cancer.

155-LB: The Increase in Endogenous Glucose Production with SGLT2 Inhibition Is Unchanged by Renal Denervation but Highly Correlates to Urinary Glucose Excretion

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 155-LB
Author(s):  
CAROLINA SOLIS-HERRERA ◽  
MARIAM ALATRACH ◽  
CHRISTINA AGYIN ◽  
HENRI HONKA ◽  
RUPAL PATEL ◽  
...  
Keyword(s):  
Renal Denervation ◽  
Glucose Production ◽  
Endogenous Glucose Production ◽  
Urinary Glucose Excretion ◽  
Urinary Glucose ◽  
Sglt2 Inhibition ◽  
Endogenous Glucose ◽  
Glucose Excretion

Abstract 16709: Contrasting Influences of Renal Function on Blood Pressure and HbA1c Reductions With Empagliflozin in Patients With Type 2 Diabetes and Hypertension

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
David Cherney ◽  
Mark Cooper ◽  
Ilkka Tikkanen ◽  
Susanne Crowe ◽  
Odd Erik Johansen ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Renal Function ◽  
Controlled Trial ◽  
Phase Iii ◽  
Vascular Effects ◽  
Antihypertensive Medications ◽  
Urinary Glucose ◽  
The Impact

The sodium glucose cotransporter 2 inhibitor empagliflozin (EMPA) reduces HbA1c, weight and blood pressure (BP) in patients with type 2 diabetes (T2D). While glucose lowering with EMPA is dependent on renal function, the impact of chronic kidney disease (CKD) on BP reduction with EMPA is less well understood. Our aim was to determine if impaired renal function attenuates antihypertensive effects of EMPA. A Phase III randomized placebo (PBO)-controlled trial (EMPA-REG BP™) investigated the efficacy and safety of EMPA in patients with T2D and hypertension (defined as mean seated office systolic BP [SBP] 130-159 mmHg and diastolic BP [DBP] 80-99 mmHg at screening). Patients (mean [SD] age 60.2 [9.0] years, HbA1c 7.90 [0.74] %, 24-hour SBP 131.4 [12.3] and 24-hour DBP 75.0 [7.8] mmHg) received EMPA 10 mg (n=276), EMPA 25 mg (n=276) or PBO (n=271) once daily for 12 weeks. We assessed changes from baseline in mean ambulatory 24-hour SBP and HbA1c in subgroups by baseline eGFR (MDRD equation), adjusting for differences in baseline mean 24-hour SBP (for SBP analyses only), HbA1c, region, number of antihypertensive medications, treatment, eGFR and treatment by eGFR interaction between groups. In patients with normal renal function, or stage 2 or 3 CKD, EMPA significantly reduced HbA1c and mean 24-hour SBP vs PBO (Table). As expected, PBO-corrected HbA1c reductions with EMPA appeared to decrease with decreasing eGFR (Table). In contrast, PBO-corrected reductions in mean 24-hour SBP with EMPA mostly appeared to increase with decreasing eGFR (Table). Unlike HbA1c, mean 24-hour SBP reductions with EMPA in patients with T2D and hypertension appear to be greater in patients with lower eGFR, indicating that SBP modulation with EMPA may involve pathways other than urinary glucose excretion such as diuretic effects, weight loss, improved glycemic control, reduced arterial stiffness or direct vascular effects.

Sign in / Sign up

Export Citation Format

Share Document